[go: up one dir, main page]

WO2011138265A3 - Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine - Google Patents

Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine Download PDF

Info

Publication number
WO2011138265A3
WO2011138265A3 PCT/EP2011/056938 EP2011056938W WO2011138265A3 WO 2011138265 A3 WO2011138265 A3 WO 2011138265A3 EP 2011056938 W EP2011056938 W EP 2011056938W WO 2011138265 A3 WO2011138265 A3 WO 2011138265A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
indole
orexin receptor
indazole derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/056938
Other languages
English (en)
Other versions
WO2011138265A2 (fr
Inventor
Jonathan Mark Bentley
Tara Davenport
Mark Slack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec OAI AG
Original Assignee
Evotec OAI AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec OAI AG filed Critical Evotec OAI AG
Publication of WO2011138265A2 publication Critical patent/WO2011138265A2/fr
Anticipated expiration legal-status Critical
Publication of WO2011138265A3 publication Critical patent/WO2011138265A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (I) dans laquelle A, R1à R8 ont la signification mentionnée dans le descriptif et les revendications. Ces composés sont utiles comme antagonistes du récepteur de l'orexine. L'invention concerne également des compositions pharmaceutiques, la préparation de ces composés, ainsi que leur production et leur utilisation comme médicament.
PCT/EP2011/056938 2010-05-03 2011-05-02 Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine Ceased WO2011138265A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161735.5 2010-05-03
EP10161735 2010-05-03

Publications (2)

Publication Number Publication Date
WO2011138265A2 WO2011138265A2 (fr) 2011-11-10
WO2011138265A3 true WO2011138265A3 (fr) 2015-06-25

Family

ID=42732252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/056938 Ceased WO2011138265A2 (fr) 2010-05-03 2011-05-02 Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine

Country Status (1)

Country Link
WO (1) WO2011138265A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
SG11201404738QA (en) 2012-02-07 2014-10-30 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
ITMI20130830A1 (it) 2013-05-22 2014-11-23 Laboratorio Chimico Int Spa Procedimento per la preparazione di ivabradina
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
JP6883045B2 (ja) 2016-02-12 2021-06-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ オレキシン受容体調節因子としてのハロ置換ピペリジン
PH12022550597A1 (en) 2019-09-16 2024-03-04 Takeda Pharmaceuticals Co Azole-fused pyridazin-3(2h)-one derivatives
WO2022119864A1 (fr) * 2020-12-01 2022-06-09 Purdue Research Foundation Composés pour le traitement du sars
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046199A2 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Composes chimiques
WO2000047577A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de phenyluree et de phenylthiouree utilises comme antagonistes des recepteurs de l'orexine
WO2000047576A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
WO2005040114A1 (fr) * 2003-10-14 2005-05-06 Oxagen Limited Composes presentant une activite antagoniste de crth2
WO2009105722A1 (fr) * 2008-02-22 2009-08-27 Irm Llc Composés et compositions comme modulateurs d'activité de gpr119

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260113B2 (en) 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
DE60110066T2 (de) 2000-06-16 2006-02-02 Smithkline Beecham P.L.C., Brentford Piperidine zur verwendung als orexinrezeptorantagonisten
WO2002089800A2 (fr) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
PL373223A1 (en) 2002-07-09 2005-08-22 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
AU2007285371A1 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
EP2161266A1 (fr) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Dérivés de benzofurane en tant qu'antagonistes du récepteur de l'orexine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046199A2 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Composes chimiques
WO2000047577A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de phenyluree et de phenylthiouree utilises comme antagonistes des recepteurs de l'orexine
WO2000047576A1 (fr) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
WO2005040114A1 (fr) * 2003-10-14 2005-05-06 Oxagen Limited Composes presentant une activite antagoniste de crth2
WO2009105722A1 (fr) * 2008-02-22 2009-08-27 Irm Llc Composés et compositions comme modulateurs d'activité de gpr119

Also Published As

Publication number Publication date
WO2011138265A2 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2011138265A3 (fr) Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine
IN2014CN04127A (fr)
MX2010003001A (es) Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
WO2012088038A3 (fr) Antagonistes de mch-1 consistant en tétrahydro-carbolines substituées par pipérazinone, leurs procédés de fabrication et utilisations
MY169986A (en) Benzimidazole-proline derivatives
WO2009016564A3 (fr) Dérivés de 2-aza-bicyclo[3.3.0]octane
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
ATE483707T1 (de) 2-cyclopropylthiazolderivate
WO2009022311A3 (fr) Dérivés du 1,2-diamido-éthylène
MX2010008993A (es) Derivados de 2-aza-biciclo-[2.2.1]heptano.
WO2012088124A3 (fr) Antagonistes de la mch-1 à base de tétrahydro-azacarboline, leurs procédés de fabrication et leurs utilisations
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2013190508A3 (fr) Dérivés de 1-[m-carboxamido(hétéro)arylméthyl]hétérocyclylcarboxamide
WO2011050054A3 (fr) Composés coumarine en tant que modulateurs de récepteurs possédant une utilité thérapeutique
WO2010140139A3 (fr) Formes cristallines de la 6-(1h-imidazol-1-yl)-2-phénylquinazoline et sels associés
WO2010131192A3 (fr) Nouveaux dérivés oxazolidinone
HK1259248A1 (zh) 作为趋化因子受体调节剂的新的1，2-双-磺醯胺衍生物
WO2009034432A3 (fr) Nouveaux composés actifs utilisés comme antagonistes des récepteurs muscariniques
WO2011156045A3 (fr) Formulation d'ezatiostat en comprimés
WO2011125006A3 (fr) Nouveaux composés sultame

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 04.02.2013

122 Ep: pct application non-entry in european phase

Ref document number: 11718036

Country of ref document: EP

Kind code of ref document: A2